HONG KONG, Sept. 11 /PRNewswire/ -- OrbusNeich’s Genous Bio-engineered R stent is feasible and safe in patients who need coronary revascularization before undeferrable non-cardiac surgery and have to discontinue dual antiplatelet therapy, according to a paper published online in the International Journal of Cardiology (Int J Cardiol. 2009 Aug 21. [Epub ahead of print]).
“The literature on an optimal strategy for high cardiovascular risk patients requiring undeferrable surgery remains limited,” said Federico Piscione, M.D., of Federico II University in Naples, Italy, lead and corresponding author of the publication. “This study adds to the body of knowledge that this Genous healing stent could allow surgical procedures to be performed soon after stent deployment and DAT (dual antiplatelet therapy) discontinuation.”
OrbusNeich’s Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.
SOURCE OrbusNeich
CONTACT: Global Media: David Schull, david.schull@russopartnersllc.com, or
Martina Schwarzkopf, martina.schwarzkopf@russopartnersllc.com, Ph.D.,
+1-212-845-4271 (office), +1-858-717-2310 (mobile), both of Russo Partners,
for OrbusNeich; David Kujawa, OrbusNeich, +1-954-730-0711 (office),
+1-305-733-7216 (mobile), dkujawa@orbusneich.com
Web site: http://www.OrbusNeich.com/
